Relationship of apolipoproteins A-1 and b, and lipoprotein(a) to cardiovascular outcomes: The aim-high trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglyceride and impact on global health outcomes)

Journal of the American College of Cardiology

Volumn 62, Issue 17, 2013, Pages 1575-1579

  Albers, John J ^a   Slee, April ^b   O'Brien, Kevin D ^a   Robinson, Jennifer G ^c   Kashyap, Moti L ^d,e   Kwiterovich Jr , Peter O ^f   Xu, Ping ^b   Marcovina, Santica M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Axio Research   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apolipoproteins; cardiovascular risk; lipoprotein(a); niacin; simvastatin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; RISK ASSESSMENT;

APO; APOLIPOPROTEIN; APOLIPOPROTEINS; CARDIOVASCULAR; CARDIOVASCULAR RISK; CV; ELISA; ENZYME-LINKED IMMUNOADSORBENT ASSAY; ERN; EXTENDED-RELEASE NIACIN; HAZARD RATIO; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; HR; LDL; LDL-C; LIPOPROTEIN(A); LOW-DENSITY LIPOPROTEIN; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; LP(A); NIACIN; SIMVASTATIN;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOALPHALIPOPROTEINEMIAS; LIPOPROTEIN(A); MALE; METABOLIC SYNDROME X; MIDDLE AGED; NIACIN; PROSPECTIVE STUDIES; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84886070404     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.06.051     Document Type: Article

References (10)

1. The AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive Statin therapy N Engl J Med 365 2011 2255 2267
2. S.M. Marcovina, J.J. Albers, B. Gabel, M.L. Koschinsky, and V.P. Gaur Effects of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurement of lipoprotein(a) ClinChem 41 1995 246 255
3. S. Lamon-Fava, S.M. Marconvina, and J.J. Albers Lp(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study J Lipid Res 52 2011 1181 1187
4. V.M.G. Maher, B.G. Brown, and S.M. Marcovina Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) JAMA 274 1995 1771 1774
5. S. Erquo, S. Kaptoge, and P.L. Perry Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
6. B.G. Nordesgaard, M.J. Chapman, K. Ray, J. Boren, F. Andreitti, and G.F. Watts Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
7. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Strffensen, and B.G. Nordestgaard Gentically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
8. D.A. Tregouët, I.R. Konig, and J. Erdmann Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease Nat Genet 41 2009 283 285
9. B.R. Jaeger, Y. Richter, and D. Nagel Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events Nat Clin Prac Cardiovasc Med 6 2009 229 239
10. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo- controlled trial in 25,673 high-risk participants of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291